Source:http://linkedlifedata.com/resource/pubmed/id/12594064
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
3
|
| pubmed:dateCreated |
2003-2-20
|
| pubmed:abstractText |
Transgenic mice, in which the level of surfactant protein (SP)-B mature peptide varied 5.6-fold between SP-B(+/-) and SP-B-overexpressing lines (SP-B+/+/+), were used to test the hypothesis that SP-B protects against endotoxin-induced lung inflammation. Intratracheal administration of endotoxin resulted in significantly lower concentration of SP-B mature peptide and elevated levels of total protein in bronchoalveolar lavage fluid of SP-B(+/-) mice compared with SP-B-overexpressing mice, indicating that endotoxin treatment leads to impairment of SP-B expression coincident with increased lung injury in SP-B(+/-) mice. Recruitment of inflammatory cells and elaboration of proinflammatory cytokines in bronchoalveolar lavage fluid were reduced in SP-B-overexpressing mice compared with SP-B(+/-) mice, suggesting that SP-B inhibited endotoxin-induced lung inflammation. Lung compliance and tissue damping were significantly decreased in SP-B(+/+) and SP-B(+/-) mice, but were not changed in SP-B(+/+/+) mice, consistent with a protective effect of SP-B. The minimum surface tension of large aggregate surfactant was significantly lower for surfactant isolated from SP-B-overexpressing mice, both in the absence and the presence of added plasma proteins. These data suggest that SP-B protected against endotoxin-induced lung inflammation by enhancing surfactant function, resulting in reduced lung injury, decreased influx of inflammatory cells, and lower cytokine levels; in contrast, levels of SP-B in SP-B(+/-) mice were further decreased by endotoxin treatment, likely exacerbating lung injury in this group.
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1044-1549
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
28
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
373-8
|
| pubmed:dateRevised |
2007-11-14
|
| pubmed:meshHeading |
pubmed-meshheading:12594064-Animals,
pubmed-meshheading:12594064-Bronchoalveolar Lavage Fluid,
pubmed-meshheading:12594064-Cytokines,
pubmed-meshheading:12594064-Endotoxins,
pubmed-meshheading:12594064-Heterozygote,
pubmed-meshheading:12594064-Inflammation,
pubmed-meshheading:12594064-Lung Compliance,
pubmed-meshheading:12594064-Lung Diseases,
pubmed-meshheading:12594064-Lung Volume Measurements,
pubmed-meshheading:12594064-Mice,
pubmed-meshheading:12594064-Mice, Inbred Strains,
pubmed-meshheading:12594064-Mice, Mutant Strains,
pubmed-meshheading:12594064-Mice, Transgenic,
pubmed-meshheading:12594064-Pulmonary Surfactant-Associated Protein B,
pubmed-meshheading:12594064-Pulmonary Surfactants,
pubmed-meshheading:12594064-Surface Tension,
pubmed-meshheading:12594064-Trachea
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
Surfactant protein B inhibits endotoxin-induced lung inflammation.
|
| pubmed:affiliation |
Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio 45229, USA.
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.
|